Ken Griffin‘s hedge fund Citadel has positioned a £305 million ($390 million) quick wager in opposition to GSK PLC GSK, marking the biggest wager in opposition to the UK pharma large in over a decade, reported the Monetary Instances.
The place, disclosed to the UK’s Monetary Conduct Authority, quantities to 0.51% of GSK’s excellent shares.
GSK’s Rally Faces A Actuality Test
GSK inventory has climbed 8.20% up to now month, fueled by a £2 billion ($2.5 billion approx.) inventory buyback and powerful HIV and most cancers drug gross sales. But, it nonetheless trails friends.
Over the previous 5 years, GSK shares have declined 17.53%, whereas the S&P 500 pharmaceutical index has surged 45%. Griffin’s quick alerts skepticism over the corporate’s long-term pipeline, particularly as its HIV medication close to a patent cliff.
Learn Additionally: Goldman Sachs Turns Bearish On Vaccine Maker Dynavax Amid Shingles And Hepatitis B Uncertainty
Hedge Funds, Analysts Are Cut up
This is not the primary time hedge funds have circled GSK. In 2021, activist investor Elliott Administration pushed for a management shake-up.
In the meantime, JPMorgan analysts view GSK’s newest earnings and steerage as “constructive,” however query the buyback’s timing. Barclays referred to as it “surprising,” whereas Jefferies deemed it “properly acquired.”
Takeaways For Buyers
GSK’s challenges have led to blended bets on its future, however traders looking for publicity to Large Pharma with out GSK’s dangers might take a look at business leaders like Eli Lilly & Co LLY and Pfizer Inc PFE.
Alternatively, the iShares U.S. Prescription drugs ETF IHE and SPDR S&P Prescription drugs ETF XPH present diversified publicity.
With Citadel betting in opposition to GSK, the inventory may see elevated volatility—making it one to observe.
Learn Subsequent:
Picture: Shutterstock
Overview Ranking:
Speculative
Market Information and Information dropped at you by Benzinga APIs
© 2025 Benzinga.com. Benzinga doesn’t present funding recommendation. All rights reserved.